One of the key questions with any cancer is, “Did we get it all?” Using exquisite sensitivity, Haystack MRD® testing enables the detection of minimal residual disease, aiding in monitoring treatment response and guiding personalized therapy decisions. By leveraging this cutting-edge technology, we can enhance patient care outcomes and optimize treatment strategies. Together, let’s drive progress in prostate cancer care and improve the lives of those affected. Learn more at: http://spr.ly/6184ABg